Abstract
Recently, the adaptor protein CrkII has been proved to function in initiating signals for proliferation and invasion in some malignancies. However, the specific mechanisms underlying insulin-like growth factor 1 (IGF-1)-CrkII signaling-induced proliferation of pancreatic ductal adenocarcinoma (PDAC) were not unraveled. In this work, PDAC tissues and cell lines were subjected to in vitro and in vivo assays. Our findings showed that CrkII was abundantly expressed in PDAC tissues and closely correlated with tumor-node-metastasis (TNM) stage and invasion. When cells were subjected to si-CrkII, si-CrkII inhibited IGF-1-mediated PDAC cell growth. In vitro, we demonstrated the upregulation of CrkII, p-Erk1/2, and p-Akt occurring in IGF-1-treated PDAC cells. Conversely, si-CrkII affected upregulation of CrkII, p-Erk1/2, and p-Akt. In addition, cell cycle and in vivo assay identified that knockdown of CrkII inhibited the entry of G1 into S phase and the increase of PDAC tumor weight. In conclusion, CrkII mediates IGF-1 signaling and further balanced PDAC biological behaviors via Erk1/2 and Akt pathway, which indicates that CrkII gene and protein may act as an effective target for the treatment of PDAC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Song W, Li Q, Wang L, et al. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. Sci Rep. 2015;5:10081.
Aung KL, Moore MJ. Metformin for pancreatic cancer. Lancet Oncol. 2015;16(7):748–9.
Blanco VM, Latif T, et al. Imaging and therapy of pancreatic cancer with phosphatidylserine-targeted nanovesicles. Transl Oncol. 2015;8:196–203.
Lamorte L, Royal I, Naujokas M, et al. Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol Biol Cell. 2002;13:1449–61.
Rodrigues SP, Fathers KE, Chan G, et al. CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells. Mol Cancer Res. 2005;3:183–94.
Iwahara T, Akagi T, Shishido T, et al. CrkII induces serum response factor activation and cellular transformation through its function in Rho activation. Oncogene. 2003;22:5946–57.
Fathers KE, Rodrigues S, Zuo D, et al. CrkII transgene induces atypical mammary gland development and tumorigenesis. Am J Pathol. 2010;176:446–60.
Hemmeryckx B, van Wijk A, Reichert A, et al. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. Cancer Res. 2001;61:1398–405.
Matsuda M, Tanaka S, Nagata S, Kojima A, Kurata T, Shibuya M. Two species of human CRK cDNA encode proteins with distinct biological activities. Mol Cell Biol. 1992;12:3482–9.
Miller CT, Chen G, Gharib TG, et al. Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene. 2003;22:7950–7.
Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008;10:R25.
Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet. 2005;37:1289–95.
Acknowledgments
This study was supported by grants to BFX from Foundation of Jilin Provincial Science & Technology Department [No. 201201044].
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, R., Wang, Q., Xu, G. et al. The adaptor protein CrkII regulates IGF-1-induced biological behaviors of pancreatic ductal adenocarcinoma. Tumor Biol. 37, 817–822 (2016). https://doi.org/10.1007/s13277-015-3876-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-015-3876-2